Computer-aided peptide-based drug design for inositol-requiring enzyme 1

Alireza Ghanbari, Amir Norouzy, N. Balmeh, Najaf Allahyari Fard, M. Moosavi
{"title":"Computer-aided peptide-based drug design for inositol-requiring enzyme 1","authors":"Alireza Ghanbari, Amir Norouzy, N. Balmeh, Najaf Allahyari Fard, M. Moosavi","doi":"10.18502/bccr.v14i4.14676","DOIUrl":null,"url":null,"abstract":"Inositol-requiring enzyme 1 (IRE1), an endoplasmic reticulum (ER) transmembrane protein with both kinase and endoribonuclease activities, plays an essential role during ER stress and its subsequent unfolded protein response (UPR). Recent evidence shows IRE1 signaling contributes to tumorigenesis and cancer progression, pointing to the therapeutic importance of this conserved arm of the UPR. Here, we employed different computational tools to design and predict short peptides with the capability of disrupting IRE1 dimerization/oligomerization, as a strategy for inhibiting its Kinase and RNase activities. A mutation-based peptide library was constructed using mCSM-PPI2 and OSPREY 3.0. The molecular interaction analyses between the designed peptides and IRE1 protein were conducted using the HADDOCK 2.2 online server, followed with molecular dynamics analysis by the GROMACS 2020 package. We then selected short peptide candidates that exhibited high affinity and best predicted physicochemical properties in complex with IRE1. Finally, online servers, such as ToxinPred and AllerTop, were used to identify the best peptide candidates that showed no significant allergenic or cytotoxic properties. These rational designed peptides with the capability of binding to IRE1 oligomerization domain can be considered as potential drug candidates for disrupting IRE1 activity in cancer and related diseases, pending for further validation by in silico and experimental studies.","PeriodicalId":504925,"journal":{"name":"Basic & Clinical Cancer Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic & Clinical Cancer Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/bccr.v14i4.14676","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Inositol-requiring enzyme 1 (IRE1), an endoplasmic reticulum (ER) transmembrane protein with both kinase and endoribonuclease activities, plays an essential role during ER stress and its subsequent unfolded protein response (UPR). Recent evidence shows IRE1 signaling contributes to tumorigenesis and cancer progression, pointing to the therapeutic importance of this conserved arm of the UPR. Here, we employed different computational tools to design and predict short peptides with the capability of disrupting IRE1 dimerization/oligomerization, as a strategy for inhibiting its Kinase and RNase activities. A mutation-based peptide library was constructed using mCSM-PPI2 and OSPREY 3.0. The molecular interaction analyses between the designed peptides and IRE1 protein were conducted using the HADDOCK 2.2 online server, followed with molecular dynamics analysis by the GROMACS 2020 package. We then selected short peptide candidates that exhibited high affinity and best predicted physicochemical properties in complex with IRE1. Finally, online servers, such as ToxinPred and AllerTop, were used to identify the best peptide candidates that showed no significant allergenic or cytotoxic properties. These rational designed peptides with the capability of binding to IRE1 oligomerization domain can be considered as potential drug candidates for disrupting IRE1 activity in cancer and related diseases, pending for further validation by in silico and experimental studies.
基于多肽的肌醇需要酶 1 计算机辅助药物设计
肌醇需要酶 1(IRE1)是一种内质网(ER)跨膜蛋白,具有激酶和内切酶活性,在ER应激及其随后的未折叠蛋白反应(UPR)中发挥着重要作用。最近的证据表明,IRE1 信号传导有助于肿瘤发生和癌症进展,这表明了 UPR 这一保守臂的治疗重要性。在这里,我们采用了不同的计算工具来设计和预测能够破坏 IRE1 二聚化/异构化的短肽,作为抑制其激酶和 RNase 活性的一种策略。利用 mCSM-PPI2 和 OSPREY 3.0 构建了一个基于突变的多肽库。使用 HADDOCK 2.2 在线服务器对设计的多肽与 IRE1 蛋白进行了分子相互作用分析,然后使用 GROMACS 2020 软件包进行了分子动力学分析。然后,我们选出了与 IRE1 复合物具有高亲和力和最佳预测理化性质的候选短肽。最后,我们使用在线服务器(如 ToxinPred 和 AllerTop)来确定没有明显过敏性或细胞毒性的最佳候选多肽。这些合理设计的多肽具有与 IRE1 寡聚化结构域结合的能力,可被视为潜在的候选药物,用于干扰 IRE1 在癌症和相关疾病中的活性,有待进一步的硅学和实验研究验证。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信